Clinicians using 18F-FDG PET on patients with cervical spinal cord compression may be able to predict an improved outcome after surgical decompression.
Imaging with 18F-FDG PET may predict outcomes for patients with degenerative cervical myelopathy, according to a study published in The Journal of Nuclear Medicine.
Researchers in Germany prospectively assessed regional changes in glucose metabolism in the cervical spinal cord using 18F-FDG PET in 20 patients with symptomatic degenerative monosegmental cervical stenosis who underwent decompressive surgery.
“To date, experiences with 18F-FDG PET in symptomatic patients with degenerative cervical spine stenosis and consecutive compressive myelopathy are very limited,” said one of the lead researchers, Norbert Galldicks, MD, in a release. "In the present study, we present the results of preoperative magnetic resonance imaging and 18F-FDG PET imaging and postoperative follow-up imaging 12 months after decompressive surgery. Imaging findings were correlated with the clinical outcome."
The researchers assessed patient functional status score, 18F-FDG uptake, and MR imaging changes pre- and postoperatively. The results showed that preoperatively, 10 patients had increased 18F-FDG uptake at the site of the spinal cord compression and were classified as myelopathy type 1.
The remaining patients had inconspicuous 18F-FDG uptake and were classified as myelopathy type 2. Postoperatively, those with myelopathy type 1 had a marked decrease in 18F-FDG uptake, but type 2 patients only demonstrated a moderate decline.
The researchers concluded that the focal glucose hypermetabolism at the level of cervical spinal cord compression may predict an improved outcome after surgical decompression.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.